Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting

ST-01 demonstrated statistically significant and durable pain reduction in men with chronic scrotal content pain at the 70 mg/ml dose compared to standard of care VANCOUVER, British Columbia — Sustained Therapeutics, Inc. (“Sustained Therapeutics” or the “Company”), a clinical-stage urologic therapeutics company advancing differentiated therapies for underserved conditions, today presented additional data from its Phase... The post Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting appeared first on Montreal Gazette .

Original source: Montreal Gazette